General

Surge in Mergers and Acquisitions in the Healthcare Sector Ahead of JPMorgan Event

As anticipation builds for the JPMorgan Healthcare Conference set to kick off on Monday, key players in the healthcare sector are gathering with high expectations of increased merger and acquisition (M&A) activities, especially following the acquisition of biotechnology companies at the end of last year. The event is expected to draw over 8,000 participants, including top delegations from major pharmaceutical manufacturers, signaling a return to regular attendance after a scaled-down guest list due to COVID-19 concerns in the previous year.

According to LSEG Deals Intelligence, pharmaceutical giants such as AbbVie (NYSE: ABBV), Bristol Myers (NYSE: BMY) Squibb, and AstraZeneca (NASDAQ: AZN) disclosed approximately $25 billion in biotechnology deals listed in the United States in December. Despite this uptick, global healthcare sector M&A activities in 2023 increased by 8% compared to the previous year, reaching $365 billion, remaining below the five-year average of $432 billion.

Mike Gaito, Global Head of Healthcare Investment Banking at JPMorgan, expressed optimism regarding the recent surge in mergers and acquisitions, attributing it to market recovery and decreasing interest rates. Gaito, set to interview CEO Jamie Dimon on the opening day of the conference, highlighted the intense interest in the emerging market for weight-loss drugs, with analysts predicting it could reach an annual total of $100 billion by the end of the decade. Pressure on companies to enter this field is evident, as exemplified by Roche’s $2.7 billion acquisition of Carmot Therapeutics and Eli Lilly’s $1.93 billion acquisition of Versanis Bio in 2023, strengthening Lilly’s obesity drug portfolio.

The conference discussions are expected to cover a range of topics, from regulatory and antitrust concerns to the funding environment and the potential impact of the 2024 U.S. presidential elections on the healthcare sector.

The event follows a robust rally on Wall Street, driven by the Federal Reserve’s expectations of interest rate cuts. In December, the SPDR S&P Biotech (NYSE: XBI) ETF, measuring the performance of the biotechnology sector, recorded an increase of over 18%. Concurrently, the yield on the U.S. 10-year Treasury bond dropped by approximately 50 basis points, easing financing costs for potential buyers.

Ali Satvat, a partner at private equity firm KKR, emphasized that the macroeconomic environment, including growth prospects and interest rates, will be a significant focus at the conference. Pharmaceutical companies like AbbVie and Bristol Myers, actively engaged in acquisitions to compensate for expected revenue losses due to expiring patents, have spent around $35 billion on deals to enhance their neurology and oncology franchises.

The annual conference at the Westin St. Francis Hotel will also see the participation of smaller pharmaceutical manufacturers, health insurers, and medical device companies. With private equity firms holding a record $2.59 trillion in unallocated capital, there is keen anticipation for investment opportunities and potential sales, as noted by Devin O’Reilly, a partner at Bain Capital.

More than 400 healthcare companies expected to attend the conference present an opportunity for rival investment banks and law firms to secure new business. Charles Ruck, an M&A partner at Latham & Watkins, humorously commented on the fierce competition among firms hosting their own events near the conference venue, each vying for clients with superior hospitality and amenities.

source: tr.investing.com / prepared by Melisa Beğiç

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button